Briefs
As the year began, we couldn’t have foreseen the unprecedented impact the COVID-19 pandemic would have on US and Global enterprises. By mid-March, we were in lock-down, and priorities for Commercial and Medical Affairs organizations in the life sciences industry shifted. Leaders were working feverishly to enable virtual and digital channels to engage with customers as well as internal teams. Companies reached out to TGaS Advisors for our guidance in navigating this uncharted territory, and we stepped up to proactively…
Read Now
Webinars
Available On Demand
Watch our webinar recording of Curt Staab, Sr. Vice President of Emerging Life Sciences Network as he draws from the latest landscape findings about how biopharma companies are finding talent, interviewing candidates and building commercial teams under the constraints of working during the pandemic.
We explore how biopharma companies are finding talent, interviewing candidates and building commercial teams under the constraints of working during the COVID-19 pandemic.
By submitting this form, creating an account, and/or using our website (or using…
Watch Now
Webinars
Available On Demand
A Biopharma Industry Perspective on the Current and Future State of Incentive Compensation
Trinity Life Sciences shares highlights from our latest TGaS Landscape report entitled, “Tenth Annual Incentive Compensation Landscape.” This highly anticipated report is based on interviews of 38 biopharmaceutical incentive compensation (IC) leaders who shared their experiences on IC planning.
The Tenth Annual edition is perhaps more critical than ever before as companies adapt IC approaches and plan amid COVID-19 challenges. From implementing COVID-specific Management by Objective (MBO)…
Watch Now
Briefs
Trinity has heard numerous organizations express frustration with their data management provider. Common challenges include quality issues, timeliness and lack of flexibility. Switching to another provider isn’t as hard as you think. In this advisory brief, we outline the top five things to keep in mind if you are considering a switch.
Please complete the form to download a copy of our Advisory Brief: Frustrated with Your Current Data Management Provider?
By submitting this form, creating an account, and/or using…
Read Now
White Papers
What is and isn’t working for drug launches amid COVID-19? Six months after COVID-19 lock-downs began, Trinity has uncovered some surprising (and some concerning) answers to key questions everyone is asking.
In this paper, we examine the trajectory of new molecular entities (NMEs) approved in late 2019 and early 2020 to understand how to drive a successful drug launch (and avoid the pitfalls) in the age of COVID-19.
By submitting this form, creating an account, and/or using our website (or…
Read Now
Scientific Publications
Cremophor EL (CrEL) is an additive (excipient) used to improve the solubility of hydrophobic drugs including certain anti-cancer drugs, like paclitaxel. Although the potential toxicities associated with CrEL are well known, the burden of CrEL-containing therapy is not well defined in the published scientific literature.
Authors
Brixner D, McKinley K, Gelder M, Oak B, Dehipawala S, Hadker N
Journal
ISPOR Meeting 2021
View publication…
Read Now
Scientific Publications
Crohn’s disease (CD) substantially impacts HRQoL, with complications such as perianal fistulas potentially increasing burden of illness. We investigated HRQoL in patients with CD and CPF and those without CPF, and for patients with CPF with and without CPF-related surgery.
Authors
Jiang J, Kuharic M, Athavale A, Fan T, Silber A, Abilash V, Hadker N, Sharpe E, Cazzetta S
Journal
ISPOR Meeting 2021
View publication…
Read Now
Scientific Publications
Recurrent pericarditis (RP) occurs in up to 30% of acute pericarditis patients with some experiencing multiple recurrences and/or complications. Treating RP with corticosteroids can increase adverse events, risk of recurrence, and potentially healthcare resource utilization. This retrospective study examined risk factors for recurrence and corticosteroid-related adverse events (CS-AEs) among RP patients.
Authors
Schwier NC, Luis SA, Hu X, Athavale A, Skaar J, Magestro M, Lim-Watson M
Journal
ISPOR Meeting 2021
View publication…
Read Now
Scientific Publications
This retrospective analysis of U.S. commercial claims data examined the clinical characteristics, healthcare resource utilization (HCRU), and costs of patients with PH.
Authors
Mucha L, Hoppe B, Silber A, Wang Z, Miyasato G, Skaar J, Langman C
Journal
Journal of Managed Care & Specialty Pharmacy; AMCP Nexus Virtual 2020
View publication…
Read Now
Scientific Publications
Primary hyperoxalurias (PH; types 1, 2, and 3) are rare genetic disorders resulting in the overproduction of oxalate in the liver and that manifest in renal complications. This study sought to quantify the healthcare resource utilization (HCRU), costs, and clinical characteristics of PH patients.
Authors
Bernd Hoppe, Abigail Silber, Gavin Miyasato, Tom Koenig, Jeffrey Skaar, Craig Langman
Journal
American Society of Nephrology; ASN Kidney Week 2020
View publication…
Read Now